ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

ISA Pharmaceuticals to present at the Virtual European Biotech Investor Day 2020

Access to live broadcast ISA presentation at Virtual European Biotech Investor Day on June 25, 2020

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron

Vaccine-Chemo Combo Shows Promise in Treating Advanced, HPV-Associated Cervical Cancer

ISA in the news: MedNous’ article on CervISA

ISA Pharmaceuticals announces CervISA publication